Background National guidelines recommend that thyroid function is assessed at diagnosis of type I diabetes (TIDM) and annually thereafter. This paper reports an audit of thyroid surveillance in accordance with this guideline. Patients 110 patients (66 males), median age 11.3 (1.2-15.7) years at diagnosis of TIDM, were monitored for 2.3 (0.7-4.2) years. Results 21/110 (19.0%) patients had abnormal thyroid function at diagnosis of TIDM. Of these, 16 had normal thyroid function on reassessment after 45 (3-540) days. Abnormalities of thyroid function occurred more commonly in children with diabetic ketoacidosis (DKA) than those who did not have DKA (9/29, 31.0% vs 12/81, 14.8%, p<0.025). At the end of the observation period, fi ve (4.5%) patients had minor abnormalities of thyroid function not requiring treatment and three (2.7%) were treated. Conclusions Transient abnormalities of thyroid function are common at diagnosis of TIDM, and therefore, thyroid hormones should not be measured at this time.
Autoimmune thyroid disease (ATD) occurs with increased prevalence in patients with type I diabetes mellitus (TIDM). 1 Subclinical hypothyroidism is associated with an increased frequency of symptomatic hypoglycaemic episodes and impaired growth. For these reasons, the National Institute for Health and Clinical Excellence (NICE) recommends that patients should be screened for disorders of thyroid function at the time of diagnosis of TIDM and annually thereafter. 2 This paper reports the fi ndings of an audit of practice in accordance with this guideline.
PATIENTS AND METHODS
The outcome of thyroid surveillance in 110 consecutive patients (66 male), median age 11.3 years (range 1.2-15.7) at diagnosis of TIDM, monitored for 2.3 years (0.7-4.2) were audited.
At diagnosis of TIDM, blood pH, base defi cit, plasma glucose and bicarbonate, serum TSH and T4 or fT4 were measured. Serum T3 was measured if there was an abnormality of thyroid function and if there was adequate sample. Diabetic ketoacidosis (DKA) was defi ned as a blood pH<7.3 or plasma bicarbonate <15 mmol/l associated with plasma glucose >11 mmol/l, ketonaemia or ketonuria. The term sick euthyroid syndrome (SES) was applied to clinically euthyroid patients with low levels of thyroid hormones.
Biochemical assessment of thyroid function was repeated if there were abnormalities at the initial assessment. Thyroxine therapy was initiated if TSH was signifi cantly elevated (>10 mu/l) on two consecutive samples with or without abnormalities of T4 or fT4, or if TSH was >4.5 mu/l and/or T4 or fT4 was low and/or the patient was symptomatic with elevated thyroid auto-antibody titres.
The frequency of abnormalities of thyroid function at diagnosis in patients who presented with DKA was compared to those without DKA using the χ 2 test.
RESULTS
Data are summarised in fi gure 1.
Patients with abnormal thyroid function at diagnosis of TIDM
Biochemical abnormalities of thyroid function were observed in 21/110 patients (19.0%) at diagnosis of TIDM, of whom 20 were clinically euthyroid. A 15.4-year old female presented with clinical and biochemical features of thyrotoxicosis. SES was diagnosed in 13 patients and TSH was elevated in seven patients (table 1) .
Twenty-nine patients presented with DKA. Abnormalities of thyroid function occurred more commonly in these patients (9/29 patients, 31.0%) compared to patients who did not have DKA (12/81, 14.8%), p<0.025.
Thyroid function at reassessment
Of the 21 patients with abnormal thyroid function at diagnosis of TIDM, thyroid function was normal in 16 (76.2%) at reassessment 45 days (3-540) after the diagnosis of TIDM. On routine surveillance, TSH was mildly elevated in two of these patients (TSH 4.35 and 5.43 mu/l) 1.6 and 1.1 years after the diagnosis of TIDM; however, neither patient met the department's criteria for treatment.
In four patients, abnormalities of thyroid function persisted at reassessment. In one of these patients, in whom thyroid function was still abnormal 45 days after the diagnosis of TIDM, thyroid function was normal at annual review and remains normal 3 years later. Among the diagnosis of TIDM. One subject required treatment for hypothyroidism 3.1 years after diagnosis of TIDM (TSH 33.9 mu/l, fT4 6.7 pmol/l, TPO Ab 838 IU/ml). The second subject was identifi ed 1.3 year following diagnosis of TIDM when TSH was mildly elevated (4.65 mu/l); however, fT4 was normal (13.5 pmol/l). Both patients were clinically euthyroid.
DISCUSSION
To our knowledge, this is the fi rst report of thyroid function at diagnosis of TIDM and during a period of routine surveillance. It was prompted by our impression that transient abnormalities of thyroid function occurred commonly at diagnosis of TIDM and compliance with the NICE guideline generated remaining three patients, two continue to have elevated plasma TSH (4.07 and 7.64 mu/l) and normal fT4 or T4, and one of these patients has elevated TPO Ab titres (207 IU/ml, normal range 0-50). The third patient complained of lethargy despite good glycaemic control 1 month following the diagnosis of TIDM. At this time, TPO antibody titre was 521 IU/ml, TSH was 5.76 mu/l and fT4 was 10 pmol/l and treatment with thyroxine was started.
Thyroid function during annual surveillance in patients with normal thyroid function at diagnosis of TIDM
Annual assessment of thyroid function identifi ed abnormalities in 2/89 patients in whom thyroid function was normal at group.bmj.com on April 21, 2011 -Published by adc.bmj.com Downloaded from a large number of repeat tests. Abnormalities of thyroid function have been described previously at diagnosis of childhood TIDM. In our population, 19% of subjects had an abnormality of thyroid function. A much higher prevalence was described in a study of 58 children of whom 50 had an abnormality of thyroid function children at diagnosis of TIDM. In 48 children, thyroid function returned to normal after treatment with insulin. 3 Serum T3, T4 and fT4 values were signifi cantly lower in children with TIDM compared to 19 healthy controls, and TSH was signifi cantly higher. In contrast to our practice, T3 was measured in all children, and this may account for the much higher prevalence of thyroid function abnormalities. A larger study of 138 children used siblings as controls. 4 Signifi cant differences in thyroid hormone levels were found in children at diagnosis of TIDM compared to controls, and the differences were most marked in children with DKA.
An effect of DKA and glycaemic control on thyroid function has been widely reported. In a cohort of children known to have TIDM levels of serum T3, T4 and fT4 were directly related to blood pH during episodes of DKA. 5 In newly diagnosed children serum T3, T4 and fT4 were inversely related to blood glucose and HbA1c 3 and in non-ketotic subjects with established TIDM, serum T4 was inversely related to HbA1c. 6 In our population, only one patient, who presented with classical features of thyrotoxicosis, required treatment for ATD at diagnosis of TIDM. A study that used TSH alone to screen for ATD found one subject out of 166 who required treatment for hypothyroidism at diagnosis of TIDM. 7 Collectively, these data suggest that the potential for identifi cation of asymptomatic patients requiring treatment is low while the risk of detecting abnormalities of uncertain signifi cance is high.
It is a weakness of this report that the time of reassessment of abnormalities of thyroid function was determined by clinical assessment and not per protocol. For this reason, these data do not contribute to our understanding of the optimal time to assess thyroid function in the newly diagnosed child. We favour a pragmatic approach and now measure thyroid function 6 weeks following the diagnosis of TIDM when blood samples can be collected simultaneously for analysis of HbA1c and thyroid function using paediatric sampling and analytical techniques.
In summary, abnormalities of thyroid function are common at diagnosis of childhood TIDM, while the prevalence of ATD is low. Biochemical assessment of thyroid function in the clinically euthyroid child should be deferred until insulin treatment is established. 
